Sulforaphane (mainly Broccoli) / SOX2 Cancer Research Results

SFN, Sulforaphane (mainly Broccoli): Click to Expand ⟱
Features:
Sulforaphane is an isothiocyanate derived from glucoraphanin, a compound found predominantly in cruciferous vegetables such as broccoli, Brussels sprouts, and cabbage. It is well known for its potent antioxidant and detoxification properties and has gained significant attention for its potential chemopreventive and anticancer effects.

Summary
1.primarily attenuates both DNMTs and HDACs, individually suppressing DNA hypermethylation and histones deacetylation, ultimately upregulating NRF2 (best known for NRF2↑)
2.Antioxidant Activity:
• Nrf2 activation leads to the upregulation of a host of antioxidant and detoxification enzymes (e.g., glutathione S-transferase, NAD(P)H:quinone oxidoreductase 1, heme oxygenase-1), which in turn decrease oxidative stress and lower ROS levels.
3.Pro-oxidant Effects in Cancer Cells and Under High-Dose Conditions (>=10uM?)
• In certain cancer cell types or at higher concentrations, sulforaphane can paradoxically lead to an increase in ROS levels.
• The elevated ROS may overwhelm the cancer cells’ antioxidant defenses, leading to oxidative stress–mediated cell death (apoptosis).
• This context-dependent pro-oxidant effect has been explored for its potential in selectively targeting cancer cells while leaving normal cells less affected.

- Might not be a good candidate for pro-oxidant strategy depending on concentration >10uM?.
- Strong Activation of Nrf2 (best known for) at low to moderate concentrations, hence reduces oxidative stress in both cancer and normal cells.
- AMPK signaling activated by SFN, high concentrations of ROS are produced
- ROS generation also results in depletion of GSH levels
- HIF-1α and VEGF inhibitor
- Might be effective against cancer stem cells
- But I would not combine that with radiation, as Sulforaphane activates the anti-oxidant master regulator of cells.
- “I very much agree: Sulforaphane is a very good addition, even more when the choice is an anti-oxidant therapy”
- well known as HDAC inhibitor (typically 5-10um concentrations)
-A transient decrease in HDAC activity has also been observed in healthy humans 3 h after providing a daily 200 µM SFN dose, resulting in a plasma concentration of SFN metabolites of 0.1–0.2 µM.


Dose/Bioavailabilty information:
SFN at a daily dose of 2.2 µM/kg body weight, with a mean plasma level of 0.13 µM Sprout 127.6 grams = 205uM±19.9 content yields SFN 0.5 to 2uM in plasma.
However, it is important to consider that at lower doses, specifically 2.5 μM, SFN resulted in a slight increase in cell proliferation by 5.18–11.84% within a 6 to 48 h treatment window.
-A therapeutic dose starts at approx 60 grams of the sprouts.
-100 g of Broccoli sprouts contain about 15–20 mg of sulforaphane
–Organic Broccoli Sprout Powder (Health Ranger) – Avmacol® – NanoPSA (a blend of NanoStilbene™ and Broccoli Sprout Extract).
- -750 mg Sulforaphane Glucosinolate in Daily One Serving (2 capsules) (30mg Sulforaphane)

Total sulforaphane metabolite concentration in plasma was the highest (>2 μM) at 3 h in human subjects who consumed fresh broccoli sprouts (40g)
-human studies with broccoli sprouts or extracts report plasma sulforaphane levels in the low micromolar range (typically 1–2 µM) after ingesting realistic, food-based quantities of sprouts (often in the range of 30–50 g of sprouts or a concentrated extract).

BroccoSprouts are young broccoli sprouts that have garnered attention because they contain high amounts of glucoraphanin—a precursor molecule to sulforaphane. Studies have shown that broccoli sprouts can have sulforaphane precursor levels (i.e., glucoraphanin levels) that are 10 to 100 times higher than those found in mature broccoli heads. Glucoraphanin content in broccoli sprouts can range anywhere from about 30 to over 100 mg per 100 grams of fresh sprouts. Once activated (e.g., during consumption when myrosinase acts on glucoraphanin), these levels translate into a significant sulforaphane yield, meaning that even a small amount of broccoli sprouts can deliver a potent dose of this bioactive compound.

Importantly, glucoraphanin itself is not bioactive. Rather, enzymatic hydrolysis by myrosinase, present in the plant tissue or in the mammalian microbiome, is necessary to form the active component, SFN.
- GFN (glucoraphanin) is hydrolyzed in vivo to SFN via the myrosinase, which is present in gut bacteria as well as the plant itself (also in Radish)
- Do not cook the vegetables, or if you do add myrosinase back in by adding radish.
- mild heat of broccoli (60–70 °C) inactivated ESP and preserved myrosinase and increased SF yield 3–7-fold
- chewing of fresh broccoli sprouts increases the interaction of glucosinolates with myrosinase and consequently, increases the bioavailability of SFN in the body

-Note half-life 2-3 hrs.
BioAv is good (15-80%) but requires myrosinase
Pathways:
- induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Lowers AntiOxidant defense in Cancer Cells: NRF2↓(contrary, actually most raises NRF2), TrxR↓**, GSH↓, Catalase↓(contrary), HO1↓(contrary), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, Hh↓, GLi↓, GLi1↓, CD133↓, β-catenin↓, sox2↓, notch2↓, nestin↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, 5↓, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 NRF2 / KEAP1 antioxidant response ↑ NRF2 (often insufficient for rescue) ↑ NRF2 (protective) Driver Electrophile-driven stress response Sulforaphane covalently modifies KEAP1, activating NRF2 signaling
2 Histone deacetylases (HDACs) ↓ HDAC activity ↔ mild modulation Driver Epigenetic reprogramming HDAC inhibition alters transcription of cell-cycle and apoptosis genes
3 Reactive oxygen species (ROS) ↑ ROS (transient / stress-inducing) ↓ ROS Secondary Redox signaling perturbation ROS rise reflects electrophilic stress rather than classic redox cycling
4 Cell cycle regulation ↑ G2/M or G1 arrest ↔ largely spared Secondary Cytostatic growth control Cell-cycle arrest is a prominent phenotype in cancer cells
5 Intrinsic apoptosis ↑ apoptosis (context-dependent) ↔ protected Phenotypic Threshold-dependent cell death Apoptosis occurs when stress exceeds adaptive capacity
6 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Secondary Suppression of inflammatory survival programs NF-κB inhibition supports anti-proliferative and anti-inflammatory effects


SOX2, SOX2: Click to Expand ⟱
Source:
Type:
SOX2 is a transcription factor that plays a crucial role in the development and maintenance of various cell types, including stem cells and progenitor cells. In the context of cancer, SOX2 has been found to be overexpressed in several types of tumors, including lung, breast, and esophageal cancers.
Overexpressed in: Lung, Breast, Esophageal, Prostate, GBM, CRC.


Scientific Papers found: Click to Expand⟱
9191- ITCs,  AITC,  BITC,  PEITC,  SFN  Molecular Targets of Isothiocyanates in Cancer: Recent Advances
- Review, Var, NA
Risk↓, Various recent epidemiological studies have indicated that consumption of cruciferous vegetables such as garden cress, broccoli, etc., reduces the risk of cancer.
TumCG↓, ITCs suppress tumor growth by generating reactive oxygen species or by inducing cycle arrest leading to apoptosis.
ROS↑,
TumCCA↑,
Apoptosis↑,
Ingr?, Some of the widely studied ITCs that have potent anti-cancer effects are Allyl isothiocyanate (AITC), Benzylisothiocyanate (BITC), Phenethylisothiocyanate (PEITC) and Sulforaphane (SFN).
chemoPv↑, Chemopreventive effects of ITCs are exerted by inhibition of the bio-activation of carcinogens. PEITC has been shown to possess significant chemopreventive properties against tobacco-induced carcinogens in rodent models of lung and esophageal cancer
P450↓, BITC suppresses cytochrome P450 2E1 while sulforaphane inhibits cytochrome P450 1A2 [
SXR↓, Sulforaphane also has been shown to inhibit steroid and xenobiotic receptor (SXR), a nuclear hormone receptor that regulates expression of CYP3A4
CYP3A4↓,
NRF2↑, ITCs induce the Nrf2 transcription factor to activate ARE
ARE↑,
HO-1↑, SFN mediated induction of Nrf2 was found to be through the activation of heme oxygenase 1 and inhibition of p38 in hepatoma cells
p38↓,
TrxR↑, several studies have shown induction of thioredoxin reductase as well its substrate thioredoxin by SFN in various cancer cell lines
Trx↑,
NF-kB↓, Inhibition of key survival pathway such as NF-kB and AP-1 by ITCs also contributes to the chemopreventive effects of ITCs [
AP-1↓,
BioAv↑, intracellular concentrations of ITCs can reach up to 100–200 folds higher than the extracellular concentrations. For example when hepatoma cells were incubated with 100μM SFN for about 30 mins, the intracellular concentrations reached about 6.4mM
Akt↓, via inhibition of key molecules overexpressed in cancer such as AKT, STAT3, HDAC and NF-kB
STAT3↓,
HDAC↓,
VEGF↓, BITC Anti-angiogenesis Pancreas ↓VEGF, MMP-2, HIF-a In vitro 5, 10,20 μM/24 h BxPC-3,PanC-1 [77] ↑RhoB ↓STAT-3 phosphorylation (Tyr-705), HIF-a, VEGFR-2, VEGF, MMP-2, CD31, RhoC.
MMP2↓,
Hif1a↓,
CD31/PECAM-1↓,
PI3K↓, BITC Apoptosis Pancreas ↓PI3K, AKT, PDK1, mTOR, FOXO1, FOXO3a In vitro 5, 10, 20 μM/24h BxPC-3,PanC-1 [55] ↑Bim, p27, and p21
PDK1 / PDPK1↓,
mTOR↓,
FOXO1↓,
FOXO3↓,
BIM↑,
p27/CDKN1B↑,
P21↑,
HER2/EBBR2↓, PEITC Apoptosis Breast ↓HER2, EGFR, STAT-3, BCL-XL, XIAP, ROS In vitro 10 μM/24 h MDA-MB-231, MCF-7 [95] ↑Bax, Bim, HER2
EGFR↓,
Bcl-xL↓,
XIAP↓,
ROS↓,
Zeb1↓, SFN Anti-metastasis Bladder ↓ZEB1, Snail In vitro 0–20μM/24h T24 [154] ↑E-cadherin
Snail↓,
E-cadherin↑,
MMP2↓, AITC Anti-metastasis Liver ↓MMP-2/-9 In vitro 0.1–5 μM/24 h SK-Hep 1
MMP9↓,
ROS↑, ROS generation leads to disruption of mitochondrial membrane potential and release of pro-apoptotic molecules resulting in activation of caspase-mediated cell death [63, 81, 83].
MMP↓,
Casp↑,
DNAdam↑, ROS induced by BITC also DNA damage and G2/M cell cycle arrest as detected through increased phosphorylation of H2A.X
TumCCA↑,
γH2AX↑,
CSCs↓, dietary BITC also suppressed the growth of cancer stem cell in MMTV-neu breast cancer transgenic mice model along with inhibition of major stem cell markers like Oct4, SOX-2 and Nanog
OCT4↓,
SOX2↓,
Nanog↓,
NOTCH2↑, In contrast, the activation of NOTCH2 signaling by BITC was found to impede the therapeutic benefits of BITC
selectivity↝, Like BITC, PEITC also induces ROS generation selectively in cancer cells
ETC↓, PEITC disrupts mitochondrial electron transport chain (ETC) by inhibiting Complex I and III activity and reduces oxygen consumption rate in prostate cancer cells
compI↓,
compIII↓,
OCR↓,
Synergy↑, ITCs exhibit a diverse range of cellular targets for anti-cancer effect. This property of ITCs makes them highly desirable for combinatorial therapeutic approaches.
ChemoSen↑, BITC:20μM (1h) Cisplatin 15, 30, 45μM (48h) Lung ↓ β-Tubulin Sensitization
RadioS↑, combination of BITC or SFN with the radiation therapy caused increased G2/M cell cycle arrest
Synergy↑, PEITC:0.025% in diet (10 and 16 weeks) Curcumin 1% in diet (10 and 16 weeks) Prostate ↓ PDK-1/AKT Synergistic
Synergy↑, SFN:25μM (24h) Resveratrol 25μM (24h) Glioma cells ↓ LDH, ↓ AKT, ↑ Caspase 3 cleavage Synergistic
Synergy↑, SFN:Quercetin Pancreatic cancer stem cells ↓ BCL-2, ↓ XIAP, ↑ Caspase 3 cleavage Synergistic
Synergy↑, SFN:10μM (6days) Epigallocatechin gallate 20μM (6days) Ovarian ↓ hTERT, ↓ BCL-2 Synergistic
Synergy↑, DIM synergizes with SFN leading to enhanced cell cycle arrest in colon cancer cells

3198- SFN,    Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells
- in-vitro, Pca, NA
Nanog↓, sulforaphane reduced the amount of Nanog, Sox2, E-cadherin, GATA-4, HNF-3β, SOX17, Otx2, TP63, Snail, VEGF R2 and HCG.
SOX2↓,
E-cadherin↓,
Snail↓,
VEGFR2/KDR/Flk1↓,
Diff↓, sulforaphane, particularly in combination with TRAIL, reduces the levels of proteins required for self-renewal, differentiation, cell migration, the epithelialmesenchymal transition (EMT) and tumorigenesis (
TumCMig↓,
EMT↓,
CXCR4↓, CXCR4 receptor, which is involved in migration and metastasis (42), was inhibited following the sulforaphane-only treatment
NOTCH1↓, Similar results were found for the Notch 1 receptor
ALDH1A1↓, Sulforaphane significantly reduced the ALDH1 activity from ∼30 to 12%; conversely
CSCs↓, data suggest that sulforaphane strongly inhibits stem cell signaling
Synergy↑, demonstrated that sulforaphane and TRAIL reduced the expression of the CSC markers CD133, CXCR4, Nanog, c-Met, EpCAM, CD44, and ALDH1 and the proliferation marker Ki67;


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ARE↑, 1,   HO-1↑, 1,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 2,   Trx↑, 1,   TrxR↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↓, 1,   compIII↓, 1,   ETC↓, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

PDK1 / PDPK1↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Bcl-xL↓, 1,   BIM↑, 1,   Casp↑, 1,   p38↓, 1,   XIAP↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   EGFR↓, 1,   HER2/EBBR2↓, 1,   mTOR↓, 1,   PI3K↓, 1,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

FOXO1↓, 1,   FOXO3↓, 1,   HDAC↓, 1,   OCT4↓, 1,   SOX2↓, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,   p27/CDKN1B↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH1A1↓, 1,   CSCs↓, 2,   Diff↓, 1,   Nanog↓, 2,   NOTCH1↓, 1,   NOTCH2↑, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 1,   EMT↓, 1,   MMP2↓, 2,   MMP9↓, 1,   Snail↓, 2,   TumCMig↓, 1,   Zeb1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

CD31/PECAM-1↓, 1,   Hif1a↓, 1,   VEGF↓, 1,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CXCR4↓, 1,   NF-kB↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

SXR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 1,   CYP3A4↓, 1,   P450↓, 1,   RadioS↑, 1,   selectivity↝, 1,   Synergy↑, 7,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   HER2/EBBR2↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoPv↑, 1,   Risk↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr?, 1,  
Total Targets: 70

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: SOX2, SOX2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:156  Target#:656  State#:%  Dir#:%
wNotes=on sortOrder:rid,rpid

 

Home Page